Supplemental Figures 1-3 and Supplemental Tables 1-9 from Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy

Supplemental Figure 1. Flow of patients and samples through study Supplemental Figure 2. Receiver operating curve (ROC) for HRD as a predictor of CA125 response in the HGSOC subset. Supplementary Table 1. Clinical characteristics and patient outcome. Supplemental Table 2. Univariate logistic regression analyses of HRD status, tBRCA and CCNE1 as predictors of CA125 response. Supplemental Table 3. Multivariate logistic regression analysis of HRD and clinical factors as predictors of CA125 Complete Response. Supplemental Table 4: Univariate and multivariate logistic regression analyses of HRD status at the predefined threshold of {greater than or equal to}42 and an exploratory threshold of {greater than or equal to}33 as predictors of CA125 response in the HGSOC subset. Supplemental Table 5. Multivariate logistic regression analysis of tBRCA and clinical factors as predictors of CA125 complete response. Supplemental Table 6: Univariate and multivariate Cox PH analyses of PFS and OS for HRD status at the predefined threshold of {greater than or equal to}42 and an exploratory threshold of {greater than or equal to}33 in the HGSOC subset. Supplemental Table 7. Progression-free survival (PFS) and overall survival (OS) according HRD status, tBRCA mutation status, and CCNE1 amplification in the overall cohort (N=250). Supplemental Table 8. Progression-free survival (PFS) and overall survival (OS) according HRD status, tBRCA mutation status, and CCNE1 amplification in the HGSCO subgroup (N=179). Supplemental Table 9. Multivariate Cox PH analyses of HRD, CCNE1 amplification and clinical factors as predictors of PFS and OS.